The proposed acquisition of Organon is aligned with Sun Pharma’s strategy of growing its Innovative Medicines business

Noveltreat is indicated for chronic weight management in adults as an adjunct to a reduced calorie diet & increased physical activity

The FDA regulatory action date for this sBLA is expected by October 29, 2026

The consolidated total income of the company increased by 13.85% at Rs 16,099.38 crore for Q3FY26

The company will launch generic semaglutide injection under the brand name -- Noveltreat

The company is recalling the affected lot due to Failed Impurity/Degradation specifications

The company continue to manufacture and supply approved products from the facility to the US market

Sun Pharma Laboratories has received approval from Board of Directors for an investment of Rs 3,000 crore

ILUMYA offers a safe and effective treatment option for patients who are struggling to manage their moderate-tosevere plaque psoriasis

Under the agreement, both companies will promote, market & distribute SZC in India under different brand names

The consolidated total income of the company increased by 9.55% at Rs 14,948.23 crore for Q2FY26

This means the FDA considers the facility to be not fully compliant with regard to certain current good manufacturing practices

Total consolidated income of the company increased by 8.57% at Rs 14315.86 crore for Q1FY26

Newly set up company will do localization of products which would be produced at prospective partners in China for sales locally

With limited treatment options available to people living with severe alopecia areata in the U.S., the need for innovative therapies such as LEQSELVI remains critically important

Sun Pharmaceutical Industries’ partner Philogen S.p.A has voluntarily withdrawn the application for marketing authorization to the European Medicines Agency for Nidlegy

At the conclusion of the inspection, the USFDA issued a Form-483, with 8 observations

The company has entered into an agreement with US based Pharmazz Inc

The total consolidated income of the company increased by 7.81% at Rs 13571.71 crore for Q4FY25

Sun Pharmaceutical Industries Inc is recalling the affected lot due to ’Cross Contamination’

While the litigation between Incyte Corporation and the company continues, the preliminary injunction is no longer in effect

The company has obtained rights from Daewoong Pharmaceutical Co, Korea to manufacture and commercialise FEXUCLUE (Fexuprazan) in India

Earlier, TARO Pharmaceuticals Inc. had entered into an agreement with Antibe Therapeutics Inc.

The company initiated the Class II nationwide (US) recall on February 6, 2025

The transaction is expected to be completed in the second calendar quarter of 2025

Within respective industries, this Yearbook aims to distinguish those companies that have demonstrated strengths in corporate sustainability

Total consolidated income of the company increased by 11.96% at Rs 14141.08 crore for Q3FY25

Antibe is currently under court-observed liquidation proceedings

The said transaction is expected to be completed by January 31, 2025

Total consolidated income of the company increased by 9.29% at Rs 13645.39 crore for Q2FY25

The two partner companies will share post-commercialization economics in about 45(Philogen):55(Sun Pharma) ratio

USFDA conducted an inspection at Company’s Dadra facility from December 4, 2023 to December 15, 2023

The New Jersey-based unit of the Mumbai-based drug major is recalling Febuxostat Tablets in 40 mg and 80 mg strengths

The cost of acquisition is around $3.05 million

This recognition attests to Sun Pharma’s commitment to incorporate Environmental, Social, and Governance principles through focused initiatives across its businesses

Taro Pharma Corporation is set up as an entity separate from Alchemee LLC, a subsidiary of Taro Israel, to help Alchemee LLC with selling its Proactiv skincare products on e-commerce marketplace in USA

Total consolidated income of the company increased by 10.65% at Rs 12630.90 crore for Q3FY24

Sun Pharmaceutical will acquire 8,086,818 shares constituting 21.52% of the total outstanding shares of Taro for a cash consideration of $43 per share amounting to Rs 2,891.76 crore

Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa

The objective of acquisition is to facilitate consolidation of business in Israel

This strategic investment is to support development of innovative pharmaceutical delivery technologies and get access to the technology for certain molecules and territories

Princeton-based Sun Pharmaceutical Industries Inc is recalling the affected lot that was produced at the drugmaker’s Dadra-based facility

Ilumetri was approved for marketing in China in May 2023

The agreement includes an upfront payment of $15 million, regulatory and commercial milestones, and royalties

Total consolidated income of the company increased by 13.12% at Rs 12486.02 crore for Q2FY24

Under the terms of this agreement, Zydus has granted Sun Pharma semi-exclusive rights to co-market the product in India

The affected lot was manufactured at Sun Pharma’s Halol-based plant in Gujarat

Sun Pharmaceutical Industries Inc is recalling the product for being ‘Subpotent’

Besides, the company has executed an additional agreement to acquire further around 4.04% equity shares in Agatsa Software

Post this acquisition, the Sun Pharma de Mexico, S.A. de C.V. would become a wholly-owned subsidiary of Sun Pharma

WINLEVI works differently from any other topical acne treatment

The company has entered into license agreement to commercialise a first-in-class innovative drug, Tyvalzi (Sovateltide) in India

The Mumbai-based drug major spent about Rs 2,400 crore on R&D in 2022-23

Total consolidated income of the company increased by 12.83% at Rs 12145.28 crore for Q1FY24

The Mumbai-based company had reported a consolidated revenue of Rs 43,278 crore in 2022-23

WINLEVI will be available in Canada this fall

Tildrakizumab Injection has also been approved for marketing in the US, EU, Japan, UK, Switzerland, Canada, Australia, Hong Kong

The two partner companies will share post commercialization economics in about 50:50 ratio

Under the indicative proposal, post the acquisition, Taro will become a wholly-owned subsidiary of Sun Pharma and will be delisted from NYSE

Total consolidated income of the company increased by 18.24% at Rs 11303.95 crore for Q4FY23

The company is recalling 24,194 prefilled syringes of Fyremadel (ganirelix acetate) injection

CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology

The company is recalling a generic drug indicated to raise blood pressure in adult patients with acute hypotension

The said acquisition is expected to be completed by the end of May 2023

This acquisition is an opportunity to bring deuruxolitinib to market globally and make a meaningful difference to alopecia areata patients around the world

The company has entered into agreements to acquire minority stake in Agatsa Software and Remidio Innovative Solutions which are non-material investments by the Company in the allied areas

The company initiated the Class II nationwide recall (US) on January 13 this year

The respective product approval is based on Revlimid Capsules, 5mg, 10mg, 15mg, 25mg and 2.5mg, 20mg as a reference product

Total consolidated income of the company increased by 10.87% to Rs 11,414.85 crore for Q3FY23

The company has acquired Disperzyme, Disperzyme-CD and Phlogam as part of the deal

SEZABY is a benzyl alcohol-free and propylene glycol-free formulation of phenobarbital sodium powder for injection

Concert is a late-stage biotechnology company pioneering the use of deuterium in medicinal chemistry

The health regulator inspected the manufacturing facility from April 26 to May 9, 2022

The company will make the drug available under the brand name, PALENO (Palbociclib) 75 mg, 100 mg, 125 mg

The USFDA has excluded 14 products from this Import Alert subject to certain conditions

The company is recalling the affected lot, produced at its Mohali plant, due to ‘discoloration’

SEZABY is a benzyl alcohol-free and propylene glycol-free formulation of phenobarbital sodium powder for injection

Currently, there are no phenobarbital injection products approved by the US FDA for the treatment of seizures in newborns

The plant was inspected in August and had received a form 483 with six observations earlier

Total consolidated income of the company increased by 12.07% to Rs 11037.50 crore for Q2FY23

At the conclusion of the inspection, the USFDA issued a Form-483, with 6 observations

Total consolidated income of the company increased by 10.73% at Rs 9560.35 crore for Q4FY22

The company, which posted revenues of Rs 38,426 crore in FY22, aims to invest 7-8 per cent of sales in the R&D front in the ongoing fiscal

The Uractiv portfolio comprises food supplements including minerals, vitamins and adjuvants; cosmetics and medical devices used for maintaining urinary tract health